190 related articles for article (PubMed ID: 33219367)
1. Genome-wide association study identifies a role for the progesterone receptor in benign prostatic hyperplasia risk.
Li W; Klein RJ
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):492-498. PubMed ID: 33219367
[TBL] [Abstract][Full Text] [Related]
2. A genetic variant near GATA3 implicated in inherited susceptibility and etiology of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS).
Na R; Helfand BT; Chen H; Conran CA; Crawford SE; Hayward SW; Tammela TLJ; Hoffman-Bolton J; Zheng SL; Walsh PC; Schleutker J; Platz EA; Isaacs WB; Xu J
Prostate; 2017 Aug; 77(11):1213-1220. PubMed ID: 28656603
[TBL] [Abstract][Full Text] [Related]
3. Heritability and genome-wide association study of benign prostatic hyperplasia (BPH) in the eMERGE network.
Hellwege JN; Stallings S; Torstenson ES; Carroll R; Borthwick KM; Brilliant MH; Crosslin D; Gordon A; Hripcsak G; Jarvik GP; Linneman JG; Devi P; Peissig PL; Sleiman PAM; Hakonarson H; Ritchie MD; Verma SS; Shang N; Denny JC; Roden DM; Velez Edwards DR; Edwards TL
Sci Rep; 2019 Apr; 9(1):6077. PubMed ID: 30988330
[TBL] [Abstract][Full Text] [Related]
4. Comparison of mRNA, Protein, and Urinary Nucleic Acid Levels of S100A8 and S100A9 between Prostate Cancer and BPH.
Yun SJ; Yan C; Jeong P; Kang HW; Kim YH; Kim EA; Lee OJ; Kim WT; Moon SK; Kim IY; Choi YH; Kim WJ
Ann Surg Oncol; 2015 Jul; 22(7):2439-45. PubMed ID: 25348783
[TBL] [Abstract][Full Text] [Related]
5. CHRDL1, NEFH, TAGLN and SYNM as novel diagnostic biomarkers of benign prostatic hyperplasia and prostate cancer.
Su Z; Wang G; Li L
Cancer Biomark; 2023; 38(2):143-159. PubMed ID: 37781794
[TBL] [Abstract][Full Text] [Related]
6. Genome-wide associations for benign prostatic hyperplasia reveal a genetic correlation with serum levels of PSA.
Gudmundsson J; Sigurdsson JK; Stefansdottir L; Agnarsson BA; Isaksson HJ; Stefansson OA; Gudjonsson SA; Gudbjartsson DF; Masson G; Frigge ML; Stacey SN; Sulem P; Halldorsson GH; Tragante V; Holm H; Eyjolfsson GI; Sigurdardottir O; Olafsson I; Jonsson T; Jonsson E; Barkardottir RB; Hilmarsson R; Asselbergs FW; Geirsson G; Thorsteinsdottir U; Rafnar T; Thorleifsson G; Stefansson K
Nat Commun; 2018 Nov; 9(1):4568. PubMed ID: 30410027
[TBL] [Abstract][Full Text] [Related]
7. Glutathione S-transferase gene variants and risk of benign prostate hyperplasia in a North Indian population.
Konwar R; Manchanda PK; Chaudhary P; Nayak VL; Singh V; Bid HK
Asian Pac J Cancer Prev; 2010; 11(2):365-70. PubMed ID: 20843117
[TBL] [Abstract][Full Text] [Related]
8. Patterns of Benign Prostate Hyperplasia Based on Magnetic Resonance Imaging Are Correlated With Lower Urinary Tract Symptoms and Continence in Men Undergoing a Robot-assisted Radical Prostatectomy for Prostate Cancer.
Grivas N; van der Roest R; Tillier C; Schouten D; van Muilekom E; Schoots I; van der Poel H; Heijmink S
Urology; 2017 Sep; 107():196-201. PubMed ID: 28601562
[TBL] [Abstract][Full Text] [Related]
9. Using Genetic and Epigenetic Markers to Improve Differential Diagnosis of Prostate Cancer and Benign Prostatic Hyperplasia by Noninvasive Methods in Mexican Patients.
Sánchez BE; Aguayo A; Martínez B; Rodríguez F; Marmolejo M; Svyryd Y; Luna L; Muñoz LA; Jiménez MA; Sotomayor M; Vargas V F; Mutchinick OM
Clin Genitourin Cancer; 2018 Aug; 16(4):e867-e877. PubMed ID: 29571584
[TBL] [Abstract][Full Text] [Related]
10. No Tumor Suppressor Role for
Koseoglu H; Celebi A; Galamiyeva G; Dalay N; Ozkardes H; Buyru N
DNA Cell Biol; 2021 Sep; 40(9):1222-1229. PubMed ID: 34370601
[TBL] [Abstract][Full Text] [Related]
11. Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care--the Triumph project.
Verhamme KM; Dieleman JP; Bleumink GS; van der Lei J; Sturkenboom MC; Artibani W; Begaud B; Berges R; Borkowski A; Chappel CR; Costello A; Dobronski P; Farmer RD; Jiménez Cruz F; Jonas U; MacRae K; Pientka L; Rutten FF; van Schayck CP; Speakman MJ; Sturkenboom MC; Tiellac P; Tubaro A; Vallencien G; Vela Navarrete R;
Eur Urol; 2002 Oct; 42(4):323-8. PubMed ID: 12361895
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive patient evaluation for benign prostatic hyperplasia.
Jepsen JV; Bruskewitz RC
Urology; 1998 Apr; 51(4A Suppl):13-8. PubMed ID: 9586591
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic investigations of canine prostatitis incidence together with benign prostate hyperplasia, prostate malignancies, and biochemical recurrence in high-risk prostate cancer as a model for human study.
Shafiee R; Shariat A; Khalili S; Malayeri HZ; Mokarizadeh A; Anissian A; Ahmadi MR; Hosseini E; Naderafif M; Mohsenzadeh S; Rasoulian MH; Rezapour R; Pourzaer M
Tumour Biol; 2015 Apr; 36(4):2437-45. PubMed ID: 25420908
[TBL] [Abstract][Full Text] [Related]
14. Potential role of glutathione S-transferase P1 gene polymorphism and metabolic syndrome in lower urinary tract symptoms attributed to benign prostatic hyperplasia.
Zhang W; Li Z; Liu M; Mu Y; He J; Chen P; Liu D; Chen K; Che B; Xu S; Zhang H; Tang K
World J Urol; 2021 Dec; 39(12):4413-4419. PubMed ID: 34228163
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of epithelial/stromal caveolin-1 expression in prostatic hyperplasia, high grade prostatic intraepithelial hyperplasia and prostatic carcinoma and its correlation with microvessel density.
Mohammed DA; Helal DS
J Egypt Natl Canc Inst; 2017 Mar; 29(1):25-31. PubMed ID: 28259631
[TBL] [Abstract][Full Text] [Related]
16. Non-steroidal anti-inflammatory drug use and the risk of benign prostatic hyperplasia-related outcomes and nocturia in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
Sutcliffe S; Grubb Iii RL; Platz EA; Ragard LR; Riley TL; Kazin SS; Hayes RB; Hsing AW; Andriole GL;
BJU Int; 2012 Oct; 110(7):1050-9. PubMed ID: 22429766
[TBL] [Abstract][Full Text] [Related]
17. Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study.
Sacco E; Bientinesi R; Marangi F; Totaro A; D'Addessi A; Racioppi M; Pinto F; Vittori M; Bassi P
BJU Int; 2012 Dec; 110(11 Pt C):E837-44. PubMed ID: 22712582
[TBL] [Abstract][Full Text] [Related]
18. Oxidised low-density lipoprotein, a possible distinguishing lipid profile biomolecule between prostate cancer and benign prostatic hyperplasia.
Asare GA; Owusu-Boateng E; Asiedu B; Amoah BY; Essendoh E; Otoo RY
Andrologia; 2019 Sep; 51(8):e13321. PubMed ID: 31145504
[TBL] [Abstract][Full Text] [Related]
19. Differential expression of androgen, estrogen, and progesterone receptors in benign prostatic hyperplasia.
Song L; Shen W; Zhang H; Wang Q; Wang Y; Zhou Z
Bosn J Basic Med Sci; 2016 Jul; 16(3):201-8. PubMed ID: 27294569
[TBL] [Abstract][Full Text] [Related]
20. [Guide dedicated to general practitioner for the management of lower urinary tract symptoms related to benign prostatic hyperplasia].
Descazeaud A; Barry Delongchamps N; Cornu JN; Azzouzi AR; Buchon D; Benchikh A; Coloby P; Dumonceau O; Fourmarier M; Haillot O; Lebdai S; Mathieu R; Misrai V; Saussine C; de La Taille A; Robert G;
Prog Urol; 2015 Jun; 25(7):404-12. PubMed ID: 25841758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
